Coverage of new genetic technologies: what matters to insurers?

M Schoonmaker, Schoonmaker M, B Bernhardt, Bernhardt B, Holtzman NA, N A Holtzman
American journal of human genetics · 1996 · vol. 59(4) , pp. A3 · PMID:11644831 · PMC1915515
Other OA: closed
📄 Open PDF View on PubMed
⚙ AI-generated summary by qwen3.7-flash, 2026-08-24 ⓘ

This paper explores the factors that influence insurance coverage decisions for new genetic technologies, focusing on what matters most to insurers.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

My notes (saved in your browser only)

MeSH descriptors

Genetic Testing Industry Insurance, Health Insurance, Health, Reimbursement Breast Neoplasms Cost-Benefit Analysis Cystic Fibrosis Data Collection Genetic Predisposition to Disease Genetic Therapy Heterozygote Humans Mass Screening Organizational Policy Pregnancy Pregnant People United States

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

Source provenance

europepmc
last seen: 2026-10-04T09:26:46.659050+00:00
pubmed
last seen: 2026-10-08T21:00:08.490831+00:00